Status:
COMPLETED
Zinc Supplementation in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus
Lead Sponsor:
Ain Shams University
Conditions:
Beta-thalassemia Major Complicated With Diabetes
Eligibility:
All Genders
10-18 years
Phase:
PHASE3
Brief Summary
Beta-thalassemia represents a group of recessive inherited hemoglobin disorders characterized by reduced synthesis of β-globin chain. The homozygous state (β-thalassemia major) "TM" results in severe ...
Detailed Description
Zinc(Zn) is a critical trace element in human health. Zinc has a potential to be utilized for the treatment of type 2 diabetes; however, evidence suggests that the effect of Zn on type 2 diabetes rema...
Eligibility Criteria
Inclusion
- Patients with β-thalassemia major and diabetes confirmed by history, examination and investigation.
- Patients on regular visits to clinic.
- Age more than 10 years old.
Exclusion
- Those who refused to lay informed consent.
- Those below age limit.
- Patients with other disorders that may affect glucose homeostasis rather than TM.
- Patients with autoimmune disease, collagen diseases, infections, tumors, hematological diseases other than Thalassemia major.
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 28 2018
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03851055
Start Date
August 1 2017
End Date
August 28 2018
Last Update
February 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nancy Elbarbary
Cairo, Egypt, 11361